PT2900279T - Antagonistas de grpr para a deteção, diagnóstico e tratamento de cancro positivo para grpr - Google Patents
Antagonistas de grpr para a deteção, diagnóstico e tratamento de cancro positivo para grprInfo
- Publication number
- PT2900279T PT2900279T PT138151816T PT13815181T PT2900279T PT 2900279 T PT2900279 T PT 2900279T PT 138151816 T PT138151816 T PT 138151816T PT 13815181 T PT13815181 T PT 13815181T PT 2900279 T PT2900279 T PT 2900279T
- Authority
- PT
- Portugal
- Prior art keywords
- grpr
- diagnosis
- detection
- cancer treatment
- antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705513P | 2012-09-25 | 2012-09-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2900279T true PT2900279T (pt) | 2019-10-14 |
Family
ID=49887190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT138151816T PT2900279T (pt) | 2012-09-25 | 2013-09-25 | Antagonistas de grpr para a deteção, diagnóstico e tratamento de cancro positivo para grpr |
Country Status (19)
| Country | Link |
|---|---|
| US (7) | US9839703B2 (https=) |
| EP (2) | EP2900279B1 (https=) |
| JP (4) | JP6562838B2 (https=) |
| KR (2) | KR102314293B1 (https=) |
| AU (4) | AU2013323596C1 (https=) |
| BR (1) | BR112015006453B1 (https=) |
| CA (2) | CA3114832A1 (https=) |
| DK (1) | DK2900279T3 (https=) |
| ES (1) | ES2745635T3 (https=) |
| HR (1) | HRP20191620T1 (https=) |
| HU (1) | HUE045724T2 (https=) |
| IL (4) | IL312551B2 (https=) |
| LT (1) | LT2900279T (https=) |
| MX (1) | MX362675B (https=) |
| PL (1) | PL2900279T3 (https=) |
| PT (1) | PT2900279T (https=) |
| RU (1) | RU2693465C9 (https=) |
| SI (1) | SI2900279T1 (https=) |
| WO (1) | WO2014052471A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2841238C (en) * | 2011-07-08 | 2019-10-01 | Biosynthema Inc. | Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors |
| PL2900279T3 (pl) * | 2012-09-25 | 2020-05-18 | Advanced Accelerator Applications Usa, Inc. | Antagonisty grpr do wykrywania, diagnostyki i leczenia raka grpr-pozytywnego |
| EP3015462A1 (en) * | 2014-10-29 | 2016-05-04 | OctreoPharm Schiences GmbH | Enantiopure chelating agents for chelator coupled pharmaceuticals, corresponding preparation method thereof and chelator coupled pharmaceuticals |
| EP3101012A1 (en) | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | New gadolinium chelate compounds for use in magnetic resonance imaging |
| US11857352B2 (en) | 2016-09-06 | 2024-01-02 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for bacterial infection |
| RU2755181C2 (ru) | 2016-11-28 | 2021-09-14 | Байер Фарма Акциенгезельшафт | Новые хелатные соединения гадолиния с высокой релаксивностью для применения в магнитно-резонансной визуализации |
| DK3568205T3 (da) | 2017-01-12 | 2023-10-09 | Radiomedix Inc | Behandling af cancerceller, der overeksprimerer somatostatinreceptorer ved at anvende radioisotop-chelaterede ocreotid-derivater |
| CN113195005B (zh) * | 2018-10-12 | 2023-07-21 | 国际先进加速器应用公司 | 包含放射性标记的grpr拮抗剂和表面活性剂的药物组合物 |
| WO2021068051A1 (en) * | 2018-11-13 | 2021-04-15 | Provincial Health Services Authority | Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders |
| CN113164628A (zh) | 2018-11-23 | 2021-07-23 | 拜耳股份有限公司 | 造影介质制剂及其制备方法 |
| CN114728088A (zh) * | 2019-09-16 | 2022-07-08 | 诺华股份有限公司 | 稳定的浓缩的放射性药物组合物 |
| TWI878344B (zh) * | 2019-09-17 | 2025-04-01 | 瑞士商諾華公司 | 放射性標記grpr拮抗劑之方法及其套組 |
| JP2022549258A (ja) * | 2019-09-24 | 2022-11-24 | ノバルティス アーゲー | セラノスティックスとして使用するための放射性標識ｇｒｐｒアンタゴニスト |
| EP4076541A1 (en) * | 2019-12-19 | 2022-10-26 | Technische Universität München | Modified grpr antagonist peptides for imaging and therapy of cancer |
| CA3246188A1 (en) | 2022-03-25 | 2023-09-28 | The University Of British Columbia | Radiolabeled compounds for in vivo imaging of the gastrin-releasing peptide (GRPR) receptor and treatment of GRPR-related disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019647A (en) | 1988-05-24 | 1991-05-28 | Merck & Co., Inc. | Gastrin releasing peptide antagonist |
| US4943561A (en) | 1988-11-28 | 1990-07-24 | Merck & Co., Inc. | Gastrin releasing peptide antagonist |
| US5028692A (en) * | 1989-04-25 | 1991-07-02 | Merck & Co., Inc. | Gastrin releasing peptide antagonist |
| IL96216A0 (en) | 1989-11-06 | 1991-08-16 | Erba Carlo Spa | Peptide derivatives,their preparation and pharmaceutical compositions containing them |
| EP0626973A1 (en) | 1992-02-07 | 1994-12-07 | Merrell Pharmaceuticals Inc. | Phenylalanine analogs of bombesin |
| US5620955A (en) * | 1993-06-18 | 1997-04-15 | Peptide Technologies Corporation | Bombesin receptor antagonists and uses thereof |
| US6545125B1 (en) | 1997-11-18 | 2003-04-08 | Chugai Seiyaku Kabushiki Kaisha | Compounds with antitumor activity |
| CA2526556C (en) | 2003-07-24 | 2012-09-25 | Bracco Imaging S.P.A. | Stable radiopharmaceutical compositions and methods for their preparation |
| EP2100900A1 (en) * | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| MX2013005697A (es) | 2010-11-22 | 2014-08-01 | Piramal Imaging Sa | Analogos de bombesina marcados con lutecio 177, para radioterapia. |
| CA2841238C (en) * | 2011-07-08 | 2019-10-01 | Biosynthema Inc. | Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors |
| PL2900279T3 (pl) * | 2012-09-25 | 2020-05-18 | Advanced Accelerator Applications Usa, Inc. | Antagonisty grpr do wykrywania, diagnostyki i leczenia raka grpr-pozytywnego |
-
2013
- 2013-09-25 PL PL13815181T patent/PL2900279T3/pl unknown
- 2013-09-25 RU RU2015115529A patent/RU2693465C9/ru active
- 2013-09-25 MX MX2015003772A patent/MX362675B/es active IP Right Grant
- 2013-09-25 AU AU2013323596A patent/AU2013323596C1/en active Active
- 2013-09-25 WO PCT/US2013/061712 patent/WO2014052471A1/en not_active Ceased
- 2013-09-25 KR KR1020207034970A patent/KR102314293B1/ko active Active
- 2013-09-25 KR KR1020157007572A patent/KR102190005B1/ko active Active
- 2013-09-25 ES ES13815181T patent/ES2745635T3/es active Active
- 2013-09-25 DK DK13815181.6T patent/DK2900279T3/da active
- 2013-09-25 US US14/431,096 patent/US9839703B2/en active Active
- 2013-09-25 PT PT138151816T patent/PT2900279T/pt unknown
- 2013-09-25 JP JP2015534625A patent/JP6562838B2/ja active Active
- 2013-09-25 SI SI201331585T patent/SI2900279T1/sl unknown
- 2013-09-25 IL IL312551A patent/IL312551B2/en unknown
- 2013-09-25 LT LT13815181T patent/LT2900279T/lt unknown
- 2013-09-25 CA CA3114832A patent/CA3114832A1/en active Pending
- 2013-09-25 IL IL276300A patent/IL276300B2/en unknown
- 2013-09-25 EP EP13815181.6A patent/EP2900279B1/en active Active
- 2013-09-25 EP EP19170067.3A patent/EP3536347A1/en active Pending
- 2013-09-25 BR BR112015006453-1A patent/BR112015006453B1/pt active IP Right Grant
- 2013-09-25 CA CA2886068A patent/CA2886068C/en active Active
- 2013-09-25 HR HRP20191620 patent/HRP20191620T1/hr unknown
- 2013-09-25 HU HUE13815181A patent/HUE045724T2/hu unknown
-
2015
- 2015-03-19 IL IL237844A patent/IL237844B/en active IP Right Review Request
-
2017
- 2017-11-20 US US15/817,776 patent/US20180133349A1/en not_active Abandoned
- 2017-12-28 IL IL256649A patent/IL256649B/en active IP Right Grant
-
2018
- 2018-06-21 AU AU2018204513A patent/AU2018204513C1/en active Active
-
2019
- 2019-06-04 JP JP2019104379A patent/JP6997135B2/ja active Active
- 2019-08-16 AU AU2019216714A patent/AU2019216714B2/en active Active
- 2019-09-24 US US16/580,990 patent/US11083805B2/en active Active
-
2021
- 2021-03-26 AU AU2021201914A patent/AU2021201914B2/en active Active
- 2021-07-23 US US17/383,550 patent/US12064489B2/en active Active
- 2021-07-23 US US17/383,577 patent/US12064491B2/en active Active
- 2021-07-23 US US17/383,567 patent/US12064490B2/en active Active
- 2021-09-22 JP JP2021154188A patent/JP7358430B2/ja active Active
-
2023
- 2023-07-13 JP JP2023115231A patent/JP7534498B2/ja active Active
-
2024
- 2024-07-15 US US18/773,055 patent/US20240366812A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2900279T (pt) | Antagonistas de grpr para a deteção, diagnóstico e tratamento de cancro positivo para grpr | |
| EP2836960A4 (en) | BIOMETRIC DETECTION | |
| ZA201504861B (en) | Apparatus for improved disease detection | |
| EP2822572A4 (en) | PEPTIDOMIMETIC MACROCYCLES | |
| GB201604325D0 (en) | Proximity detection using instrumented cutting elements | |
| PT2882440T (pt) | Combinações farmacêuticas compreendendo um inibidor de braf, um inibidor de egfr e opcionalmente um inibidor de pi3k-alfa | |
| PT2934185T (pt) | Solubilizado de curcumina | |
| GB201218555D0 (en) | Immunoassay using electrochemical detection | |
| EP2854625A4 (en) | CLOGGING DETECTION | |
| EP2902807A4 (en) | RADIOGRAPH DETECTION DEVICE | |
| HRP20181576T8 (hr) | Blok za dijagnosticiranje transakcije | |
| BR112014028738A2 (pt) | dispositivo de monitoramento de estado de ferrovia | |
| BR112014027937A2 (pt) | estação de imagem corporal total e dispositivo de imagem corporal total. | |
| PT2876447T (pt) | Método para deteção de cancro | |
| BRDI7102911S (pt) | Configuração aplicada em conjunto de segurança para coleta de sangue | |
| EP3925535C0 (en) | CARDIAC ACTIVATION TIME DETECTION | |
| PT2876446T (pt) | Método para deteção de cancro | |
| LT2900230T (lt) | Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai | |
| BR302012006416S1 (pt) | Configuração aplicada em traquéia para dispositivos de inalação. | |
| EP2917731A4 (en) | DIAGNOSTIC, PROGNOSTIC, THERAPEUTIC AND SCREENING PROTOCOLS | |
| BR112014026557A2 (pt) | fralda descartável. | |
| SG10201405620RA (en) | Stall condition detection | |
| EP2814415C0 (en) | ELECTROSURGICAL INSTRUMENT | |
| CO7091176A2 (es) | Diagnóstico farmacéutico | |
| GB2511755B (en) | Event Detection |